Biologically Effective Dose (BED) Correlation With Biochemical Control After Low-Dose Rate Prostate Brachytherapy for Clinically Low-Risk Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 1, 2010, Pages 139-146

  Miles, Edward F ^a   Nelson, John W ^a   Alkaissi, Ali K ^a   Das, Shiva ^a   Clough, Robert W ^a   Broadwater, Gloria ^a   Anscher, Mitchell S ^a   Chino, Junzo P ^a   Oleson, James R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biochemical control; Brachytherapy; Dosimetry; Prostate cancer

Indexed keywords

BIOCHEMICAL CONTROL; BIOCHEMICAL FAILURE; BIOCHEMICAL RELAPSE-FREE SURVIVAL; BIOLOGICALLY EFFECTIVE DOSE; BRACHYTHERAPY; CLONOGENS; COVARIATES; CUT POINT; DOSE DISTRIBUTIONS; DOSE-VOLUME HISTOGRAMS; FREEDOM FROM BIOCHEMICAL FAILURES; GLEASON SCORES; HIGHLY-CORRELATED; LOW DOSE; MEDICAL CENTER; OVERALL SURVIVAL; PEARSON COEFFICIENT; PRE-TREATMENT; PROPORTIONAL HAZARDS; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; SURVIVAL PROBABILITIES; TUMOR LOCATION; TUMOR REPOPULATION; UNIVARIATE;

DOSIMETERS; DOSIMETRY; HOSPITALS; PROBABILITY DISTRIBUTIONS; RADIOTHERAPY; TUMORS;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DOSIMETRY; FOLLOW UP; GLEASON SCORE; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RADIATION DOSE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALLADIUM; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RELATIVE BIOLOGICAL EFFECTIVENESS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 77950591921     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.052     Document Type: Article

References (41)

1. Lee W.R., Moughan J., Owen J.B., et al. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: A comprehensive survey of prostate brachytherapy in the United States. Cancer 98 (2003) 1987-1994
2. Beyer D.C., Thomas T., Hilbe J., et al. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy 2 (2003) 77-84
3. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
4. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
5. Kwok Y., DiBiase S.J., Amin P.P., et al. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 53 (2002) 588-594
6. Potters L., Cha C., Oshinsky G., et al. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 5 (1999) 301-306
7. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: Radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71 (2004) 29-33
8. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
9. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 46 (2000) 221-230
10. Ash D., Al-Qaisieh B., Bottomley D., et al. The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer. Radiother Oncol 79 (2006) 185-189
11. Khaksar S.J., Laing R.W., Henderson A., et al. Biochemical (prostate-specific antigen) relapse-free survival and toxicity after 125I low-dose-rate prostate brachytherapy. BJU Int 98 (2006) 1210-1215
12. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
13. Papagikos M.A., Deguzman A.F., Rossi P.J., et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V(100) superior to D(90)?. Brachytherapy 4 (2005) 252-258
14. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
15. Robert Lee W., Deguzman A.F., McMullen K.P., et al. Dosimetry and cancer control after low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 52-59
16. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
17. Willins J., and Wallner K. CT-based dosimetry for transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 39 (1997) 347-353
18. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 22 (1995) 209-234
19. 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 57 (2003) 1297-1303
20. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 58 (1985) 515-528
21. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
22. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
23. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
24. Wang J.Z., Guerrero M., and Li X.A. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 55 (2003) 194-203
25. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
26. Cox D.R. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 34 (1972) 187-220
27. Youden W.J. Index for rating diagnostic tests. Cancer 3 (1950) 32-35
28. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
29. Miles E.F., Nelson J.W., Alkaissi A.K., et al. Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer. Brachytherapy 7 (2008) 206-211
30. Stone N.N., Potters L., Davis B.J., et al. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 69 (2007) 1472-1477
31. Stone N.N., Potters L., Davis B.J., et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73 (2009) 341-346
32. 125I for prostate permanent implant brachytherapy. Int J Radiat Oncol Biol Phys 72 (2008) 247-254
33. Wang J.Z., and Li X.A. Impact of tumor repopulation on radiotherapy planning. Int J Radiat Oncol Biol Phys 61 (2005) 220-227
34. Djajaputra D., and Wu Q. On relating the generalized equivalent uniform dose formalism to the linear-quadratic model. Med Phys 33 (2006) 4481-4489
35. Zhou S.M., Das S., Wang Z., et al. Relationship between the generalized equivalent uniform dose formulation and the Poisson statistics-based tumor control probability model. Med Phys 31 (2004) 2606-2609
36. Zhou S.M., Das S.K., Wang Z., et al. Self-consistent tumor control probability and normal tissue complication probability models based on generalized EUD. Med Phys 34 (2007) 2807-2815
37. Li X.A., Wang J.Z., Stewart R.D., et al. Dose escalation in permanent brachytherapy for prostate cancer: Dosimetric and biological considerations. Phys Med Biol 48 (2003) 2753-2765
38. Wang J.Z., and Li X.A. Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose. Med Phys 30 (2003) 34-40
39. Wang J.Z., Mayr N.A., Nag S., et al. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy. Med Phys 33 (2006) 1025-1032
40. Wang J.Z., Li X.A., and Mayr N.A. Dose escalation to combat hypoxia in prostate cancer: A radiobiological study on clinical data. Br J Radiol 79 (2006) 905-911
41. Chen Z., and Nath R. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives. Int J Radiat Oncol Biol Phys 55 (2003) 825-834